{"id":"NCT00837967","sponsor":"AstraZeneca","briefTitle":"Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients","officialTitle":"A Comparison of Tolerability of 10 Inhalations of Symbicort® Turbuhaler® 160/4.5 μg and 10 Inhalations of Terbutaline Turbuhaler® 0.4 mg on Top of Symbicort® Turbuhaler® 160/4.5 μg 1 Inhalation Bid, Randomized, Double-blind, Cross Over, Phase III Study in Japanese Adults Asthma Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2009-07","completion":"2009-07","firstPosted":"2009-02-06","resultsPosted":"2012-08-29","lastUpdate":"2012-08-29"},"enrollment":25,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Symbicort Turbuhaler","otherNames":[]},{"type":"DRUG","name":"Terbutaline Turbuhaler","otherNames":[]}],"arms":[{"label":"First Symbicort, then Terbutaline","type":"EXPERIMENTAL"},{"label":"First Turbuhaler, then Symbicort","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to compare the tolerability of Symbicort® Turbuhaler® 160/4.5 μg 10 inhalations with terbutaline Turbuhaler® 0.4 mg 10 inhalations for 3 days on top of Symbicort® Turbuhaler® 160/4.5 μg 1 inhalation twice a day (bid) in adult asthma patients.","primaryOutcome":{"measure":"Adverse Events","timeFrame":"3 days","effectByArm":[{"arm":"Symbicort","deltaMin":14,"sd":null},{"arm":"Terbutaline","deltaMin":24,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":2,"countries":["Japan"]},"refs":{"pmids":["22024920"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Tremor","Blood Pressure Decreased","Nasopharyngitis","Palpitations","Tachycardia"]}}